Related Experiment Video For anti-tumor drugs
Updated: Feb 13, 2026
Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model
Published on: March 20, 2020
Impact of quality control indicator system management program on neoadjuvant and adjuvant therapies for breast
Silu Xu1, Nianyang Ding1, Lili Zhang2
1Department of Pharmacy, Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research & The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, Jiangsu, China.
Background:
Breast cancer (BC) management in China faces significant challenges, particularly in terms of standardizing diagnosis and treatment protocols across various healthcare settings. The implementation of a quality control (QC) indicator system offers a potential solution to improve treatment consistency and outcomes. This study evaluated the impact of a QC indicator system on the standardization of neoadjuvant and adjuvant therapies for BC.
Methods:
A QC system was developed by an expert panel in alignment with China's 2022 guidelines. A comparative study was conducted between Jiangsu Cancer Hospital (experimental, implementing PDCA-cycle management) and Nantong Tumor Hospital (control, routine practices). Key indicators included cTNM staging completeness, chemotherapy record standardization, and rational anti-tumor drug use. Additionally, clinical outcomes, patient-reported outcomes (PROs), and treatment adherence were assessed, alongside qualitative data derived from clinical records.
Results:
After the QC system was implemented, Jiangsu Cancer Hospital demonstrated significant improvements: cTNM staging completeness increased from 92.5% to 98.08%, chemotherapy record standardization improved by 66.65%, and rational drug use rose from 78% to 87.5% (all P<0.05). In contrast, no significant improvements were observed in the control hospital. The clinical outcomes and patient-reported symptoms also demonstrated favorable trends in the intervention hospital. Qualitative data revealed facilitators such as clearer treatment protocols and improved coordination, while challenges included increased documentation workload.
Conclusions:
The QC system effectively enhanced the standardization of neoadjuvant and adjuvant therapies for breast cancer, with improvements in clinical management and rational drug use. These results offer a scalable model for improving breast cancer management quality in other regions and institutions. Further research, including multi-center studies with extended follow-up, is recommended to validate these findings and explore the long-term impact of QC interventions on patient outcomes.
Related Concept Videos
01:05Quality Control
Quality control helps track data, visualize trends, and identify variations, making it easier to detect deviations that may affect the accuracy of an analysis. One way to do this is by generating a quality control chart, which...
02:39Indicators
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
01:20Comparing the Survival Analysis of Two or More Groups
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:03Drug Control Governance: Regulatory Bodies and Their Impact